Pfiz­er's Xalko­ri fol­low-up, which smoked the old­er drug in 1st-line pa­tients, scores dou­ble win at the FDA

De­spite be­ing the first to mar­ket in ALK-pos­i­tive non-small cell lung can­cer, Pfiz­er’s Xalko­ri lan­guished on the shelf as oth­er com­peti­tors out­paced it. Now, af­ter Pfiz­er’s fol­low-up drug ab­solute­ly smoked Xalko­ri in first-line pa­tients, the FDA is tak­ing no­tice.

In one fell swoop, the agency ap­proved Lor­bre­na as a first-line treat­ment for pa­tients with anaplas­tic lym­phoma ki­nase (ALK)-pos­i­tive NSCLC and ex­tend­ed the drug’s 2018 ac­cel­er­at­ed ap­proval to a full ap­proval, Pfiz­er an­nounced on Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER